Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Pazdur

Showing results (41-50 of 468) with videos related to

Pageof 47
Sort By:
Journal of the National Cancer Institute|October 24, 2017
Real-world Data for Clinical Evidence Generation in OncologySean Khozin, Gideon M Blumenthal, Richard Pazdur
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2024
The Retrofit: Lessons From Sotorasib's Dosing ConundrumHarpreet Singh, Paz J Vellanki, Richard Pazdur
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
End points and United States Food and Drug Administration approval of oncology drugsJohn R Johnson, Grant Williams, Richard Pazdur
The New England Journal of Medicine|April 20, 2017
Reevaluating Eligibility Criteria - Balancing Patient Protection and Participation in Oncology TrialsJulia A Beaver, Gwynn Ison, Richard Pazdur
JCO Oncology Practice|June 29, 2023
Advancing Therapies for Asian Americans, Native Hawaiians, and Other Pacific Islanders With Cancer: OCE's Project ASIATICAJennifer J Gao, Richard Pazdur, Tamy Kim
JAMA Oncology|October 8, 2020
US Food and Drug Administration Support for Oncology Drug Development During COVID-19Kushal T Kadakia, Richard Pazdur, Anand Shah
The Oncologist|September 10, 2009
Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancerMartin H Cohen, Robert Justice, Richard Pazdur
JAMA Oncology|November 6, 2015
Next-Generation Sequencing in Oncology in the Era of Precision MedicineGideon M Blumenthal, Elizabeth Mansfield, Richard Pazdur
JAMA Oncology|September 16, 2016
Minimal Residual Disease as a Potential Surrogate End Point-Lingering QuestionsNicole J Gormley, Ann T Farrell, Richard Pazdur
JAMA Oncology|June 30, 2017
Treatment Beyond Progression With Immune Checkpoint Inhibitors-Known UnknownsGideon M Blumenthal, Marc R Theoret, Richard Pazdur
Pageof 47

Showing results (41-50 of 468) with videos related to

Sort By:
Pageof 47
Journal of the National Cancer Institute|October 24, 2017
Real-world Data for Clinical Evidence Generation in OncologySean Khozin, Gideon M Blumenthal, Richard Pazdur
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2024
The Retrofit: Lessons From Sotorasib's Dosing ConundrumHarpreet Singh, Paz J Vellanki, Richard Pazdur
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
End points and United States Food and Drug Administration approval of oncology drugsJohn R Johnson, Grant Williams, Richard Pazdur
The New England Journal of Medicine|April 20, 2017
Reevaluating Eligibility Criteria - Balancing Patient Protection and Participation in Oncology TrialsJulia A Beaver, Gwynn Ison, Richard Pazdur
JCO Oncology Practice|June 29, 2023
Advancing Therapies for Asian Americans, Native Hawaiians, and Other Pacific Islanders With Cancer: OCE's Project ASIATICAJennifer J Gao, Richard Pazdur, Tamy Kim
JAMA Oncology|October 8, 2020
US Food and Drug Administration Support for Oncology Drug Development During COVID-19Kushal T Kadakia, Richard Pazdur, Anand Shah
The Oncologist|September 10, 2009
Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancerMartin H Cohen, Robert Justice, Richard Pazdur
JAMA Oncology|November 6, 2015
Next-Generation Sequencing in Oncology in the Era of Precision MedicineGideon M Blumenthal, Elizabeth Mansfield, Richard Pazdur
JAMA Oncology|September 16, 2016
Minimal Residual Disease as a Potential Surrogate End Point-Lingering QuestionsNicole J Gormley, Ann T Farrell, Richard Pazdur
JAMA Oncology|June 30, 2017
Treatment Beyond Progression With Immune Checkpoint Inhibitors-Known UnknownsGideon M Blumenthal, Marc R Theoret, Richard Pazdur
Pageof 47